Table 1:

Eligibility Criteria for ALLIANCE A082002 Trial:

1.	Histologic/cytologic documentation of stage IV NSCLC or stage III in patients who are not candidates for standard chemo-radiotherapy
2.	PD-L1 Tumor Proportion Score (TPS) TPS < 1% based on local testing
3.	EGFR, ALK and ROS1 (−)* based on local testing
4.	Measurable disease with at least one lesion amenable to SBRT
5.	ECOG Performance Status 0-2
6.	No Prior Treatment for this malignancy
7.	No comorbid conditions that would preclude immunotherapy
8.	Age ≥18 years
9.	No active other malignancies
10.	No live vaccines within 30 days
11.	Organ function criteria:
	Absolute neutrophil count ≥1500/mm3
	Platelet count ≥100,000
	Creatinine Clearance ≥45 mL/minute
	Total Bilirubin ≤1.5 x Normal
	AST/ALT ≤2.5 x Normal
12.	Treated or small asymptomatic brain metastasis patients are eligible

^*epidermal growth factor receptor, anaplastic lymphoma kinase